Merck creates thousands of jobs in Delaware with new biologics center

In a significant development for the U.S. pharmaceutical industry, Merck has initiated the construction of a $1 billion biologics center in Wilmington, Delaware. This project represents a strategic move to bolster domestic manufacturing capabilities and enhance the security of drug supply within the United States. Merck's CEO, Robert Davis, articulated the company’s vision during an appearance on "Mornings with Maria," emphasizing the importance of having both drug substance and product manufactured in the U.S., as opposed to relying solely on contract manufacturing outside the country. As part of this investment, the Wilmington facility is expected to not only serve the U.S. market but also facilitate supply for European patients. Davis pointed out that while there are ongoing operations in Ireland, the focus of this biologics center is to strengthen the supply chain's resilience. He explained that this dual approach would ensure patients receive timely access to vital medications, regardless of geopolitical or logistical challenges that may arise. The biologics center will encompass laboratory, manufacturing, and warehouse capabilities, specifically aimed at advancing next-generation biologics and therapies. Notably, it will include production capabilities for KEYTRUDA, an immunotherapy drug commonly used in cancer treatment. The initial phase of the project is projected to create approximately 4,000 construction jobs, with an additional 500 full-time positions available once the facility is operational. Davis indicated the potential for the workforce to grow, estimating a future workforce of 2,000 employees alongside 30,000 construction workers throughout the project's duration. In summary, this investment not only aligns with Merck's commitment to expanding its product pipeline but also heralds a new era of job creation and economic opportunity in Delaware. By enhancing local production capabilities, Merck is proactively addressing national security concerns regarding the U.S. drug supply, ensuring that American patients have reliable access to essential medications amidst an evolving global landscape.